Choose Your Country or Region

Anti-Serotonin transporter Rabbit Antibody [B14A13]

Catalog No.: F4067

Application: Reactivity: Human

Usage Information

Dilution
WB1:500 - 1:5000 IHC1:50 - 1:200

Application
WB, IHC

Reactivity
Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
71,75 kDa 71 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Datasheet & SDS

Biological Description

Specificity
Anti-Serotonin transporter Rabbit Antibody [B14A13] detects endogenous levels of total Serotonin transporter protein.

Clone
B14A13

Synonym(s)
HTT, SERT, SLC6A4, Sodium-dependent serotonin transporter, 5HT transporter, Solute carrier family 6 member 4, 5HTT

Background
The serotonin transporter (SERT) plays a critical role in regulating serotonergic neurotransmission by clearing serotonin (5-HT) from the synaptic cleft back into presynaptic neurons, effectively terminating serotonin signaling. SERT is a membrane protein with 12 transmembrane helices that couples serotonin reuptake to sodium and chloride ion gradients, operating through a well-defined transport cycle where serotonin first binds to an outward-facing site along with sodium and chloride ions, followed by conformational changes that release serotonin into the cytoplasm. SERT regulates extracellular serotonin concentration, thereby exerting a significant influence over mood, cognition, sleep, and appetite. Regulation of SERT involves multiple pathways: phosphorylation by kinases such as protein kinase C (PKC) and protein kinase G (PKG) modulates its activity and trafficking between the plasma membrane and intracellular compartments; lipid membrane components, including cholesterol and PIP2, affect SERT conformation, oligomerization, and surface expression; and protein-protein interactions fine-tune its localization and function. SERT possesses both a central substrate binding site and an allosteric site that modulates serotonin and inhibitor binding, which is fundamental to the mechanisms of antidepressant drugs like SSRIs (e.g., citalopram, paroxetine), that block reuptake by binding to SERT and increasing serotonin availability. Dysregulation or genetic variants of SERT are associated with neuropsychiatric disorders, including depression, anxiety, and obsessive-compulsive disorder.

Background

The serotonin transporter (SERT) plays a critical role in regulating serotonergic neurotransmission by clearing serotonin (5-HT) from the synaptic cleft back into presynaptic neurons, effectively terminating serotonin signaling. SERT is a membrane protein with 12 transmembrane helices that couples serotonin reuptake to sodium and chloride ion gradients, operating through a well-defined transport cycle where serotonin first binds to an outward-facing site along with sodium and chloride ions, followed by conformational changes that release serotonin into the cytoplasm. SERT regulates extracellular serotonin concentration, thereby exerting a significant influence over mood, cognition, sleep, and appetite. Regulation of SERT involves multiple pathways: phosphorylation by kinases such as protein kinase C (PKC) and protein kinase G (PKG) modulates its activity and trafficking between the plasma membrane and intracellular compartments; lipid membrane components, including cholesterol and PIP2, affect SERT conformation, oligomerization, and surface expression; and protein-protein interactions fine-tune its localization and function. SERT possesses both a central substrate binding site and an allosteric site that modulates serotonin and inhibitor binding, which is fundamental to the mechanisms of antidepressant drugs like SSRIs (e.g., citalopram, paroxetine), that block reuptake by binding to SERT and increasing serotonin availability. Dysregulation or genetic variants of SERT are associated with neuropsychiatric disorders, including depression, anxiety, and obsessive-compulsive disorder.

References
https://pubmed.ncbi.nlm.nih.gov/27049939/ https://pubmed.ncbi.nlm.nih.gov/30809118/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%